- Home
- TMP vs NVCR Comparison
TMP vs NVCR Comparison
Compare TMP & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMP | NVCR |
|---|---|---|
| Founded | 1836 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TMP | NVCR |
|---|---|---|
| Price | $99.42 | $13.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $105.50 | $25.71 |
| AVG Volume (30 Days) | 89.9K | ★ 1.7M |
| Earning Date | 10-23-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 126.16 | 21.79 |
| EPS | ★ 5.86 | N/A |
| Revenue | $75,742,000.00 | ★ $655,353,000.00 |
| Revenue This Year | N/A | $12.91 |
| Revenue Next Year | $7.47 | $9.23 |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $64.16 | $9.82 |
| 52 Week High | $105.00 | $21.45 |
Technical Indicators
Market Signals| Indicator | TMP | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 40.06 |
| Support Level | $95.19 | $11.73 |
| Resistance Level | $102.07 | $18.43 |
| Average True Range (ATR) | 2.72 | 0.81 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 25.10 | 33.69 |
Price Performance
Historical ComparisonAbout TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.